Latent-TGF-β: An overview

Molecular and Cellular Biochemistry

Volumn 219, Issue 1-2, 2001, Pages 163-170

  Lawrence, D A ^a  

^a DIF   (France)

Author keywords

Acidic microenvironments; Activation; Atherosclerosis; Cancer; Fibrosis; Latent TGF ; Plasmin; Thrombospondin; Transforming growth factor (TGF )

Indexed keywords

ISOPROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG ACTIVITY; LATENT PERIOD; MEDICAL RESEARCH; NONHUMAN; PATHOLOGY; PHYSICAL DISEASE; PUBLICATION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; BIOTRANSFORMATION; CARRIER PROTEINS; FIBROSIS; HUMANS; HYDROGEN-ION CONCENTRATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LATENT TGF-BETA BINDING PROTEINS; NEOPLASMS; PROTEIN ISOFORMS; RADIATION, IONIZING; SOLUBILITY;

EID: 0035060939     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010819716023     Document Type: Article

References (99)

1. Transforming growth factor production by chemically transformed cells
2. New class of transforming growth factors potentiated by epidermal growth factor: Isolation from non neoplastic tissues
3. Normal embryo fibroblasts release transforming growth factors in a latent form
4. Growth inhibitor from BSC-1 cells closely related to the platelet type β transforming growth factor
5. The cell biology of transforming growth factor-β
6. Physicochemical activation of recombinant latent Transforming Growth Factor-betas 1, 2 and 3
7. TGF-β-receptor-mediated signaling
8. Transcriptional control by the TGF-β/Smad signaling system
9. The future of recombinant growth factors in wound healing
10. Phase I trial of transforming growth factor beta 2 in chronic progressive MS
11. Comparison of recombinant transforming growth factor-beta-2 and placebo as an adjunctive agent for macular hole surgery
12. Phase I study of transforming growth factor-beta-3 mouth-washes for prevention of chemotherapy-induced mucositis
13. Transforming growth factor-β: A general review
14. Conversion of a high molecular weight latent beta-TGF from chicken embryo fibroblasts into a low molecular weight active beta-TGF under acidic conditions
15. Beta-transforming growth factor is stored in human blood platelets as a latent high molecular weight complex
16. Transforming Growth Factor-β: Latent forms, binding proteins and receptors
17. Processing of transforming growth factor β1 precursor by human furin convertase
18. A role of the latent TGF-β1-binding protein in the assembly and secretion of TGF-β1
19. Latent transforming growth factor-β binding proteins (LTBPs) - Structural extracellular matrix proteins for targeting TGF-β action
20. 2-Macroglobulin
21. Steroidogenic adrenocortical cells synthesize alpha 2-macroglobulin in vitro, not in vivo
22. Demonstration of an alpha 2-macroglobulin receptor in human fibroblasts, absent in tumor-derived cell lines
23. 2-macroglobulin-cytokine interactions based on affinity of noncovalent association in solution under apparent equilibrium conditions
24. 2-macroglobulin inactive complex
25. 2-macroglobulin: A binding protein for TGF-β and various cytokines
26. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta
27. Decorin core protein fragment leu155-val260 interacts with TGF-β but does not complete for Decorin binding to type I Collagen
28. Receptor-mediated endocytosis of deocorin: Involvement of leukocine-rich repeat structures
29. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney
30. Selective inactivity of TGF-β/decorin complexes
31. A transforming growth factor β2 (TGF-β2)-like immunosuppressive factor in amniotic fluid and localisation of TGFβ2 mRNA in the pregnant uterus
32. The immunodulatory activity of human amniotic fluid can be correlated with transforming growth factor-beta 1 (TGF-beta 1) and beta 2 activity
33. Biochemical screening for Down syndrome
34. Gender of offspring and maternal breast cancer risk
35. Role of transforming growth factor β in human disease
36. Transforming growth factor-beta bound to soluble derivatives of the beta amyloid precursor protein of Alzheimer's disease
37. Physiological and pathological interrelationships of amyloid beta peptide and the amyloid precursor protein
38. TGF-beta(1), regulation of Alzheimer amyloid precursor protein mRNA expression in a normal human astrocyte cell line: mRNA stabilization
39. Regulation of osteogenesis by fetuin
40. Acidic cellular environments: Activation of latent TGF-β and sensitization of cellular responses to TGF-β and EGF
41. Microelectode studies of the acid microenvironment beneath adherent macrophages and osteoclasts
42. How the osteoclast degrades bone
43. Breast cancer cells have a high capacity to acidify extracellular milieu by a dual mechanism
44. An activated form of transforming growth factor β is produced by cocultures of endothelial cells and pericytes
45. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: Activation of a latent transforming growth factor-β1-like molecule by plasmin during co-culture
46. Characterization of the activation of latent TGF-β by co-cultures of endothelial cells and pericytes or smooth muscle cells: A self-regulating system
47. Proteolytic activation of latent transforming growth factor-β from fibroblast-conditioned medium
48. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis
49. Cell-associated activation of latent transforming growth factor-beta by calpain
50. Mechanism of activation of latent transforming growth factor beta 1 by plasmin
51. Cellular activation of latent transforming growth factor-β requires binding to the cation-independent mannose-6-phosphate/insulin-like growth factor type II receptor
52. M6P/IGFII-receptor complexes urokinase receptor and plasminogen for activation of transforming growth factor-beta1
53. Role of urokinase in the activation of macrophage-associated TGF-beta in silica-induced lung fibrosis
54. Role of the latent TGF-β binding protein in the activation of latent TGF-β by co-cultures of endothelial and smooth muscle cells
55. Latent transforming growth factor-β1 associates to fibroblast extracellular matrix via latent TGF-β binding protein
56. Regulation of cell surface tissue transglutaminase: Effects on matrix storage of latent transforming growth factor-beta binding protein-1
57. Latent transforming growth factor-β binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-β
58. Requirement for transglutaminase in the activation of latent transforming growth factor-β in bovine endothelial cells
59. Mechanism of retinoid-induced activation of latent transforming growth factor-β in bovine endothelial cells
60. Effects of retinol on activation of latent transforming growth factor-beta by isolated osteoclasts
61. Retinoic acid stimulates plasminogen activator inhibitor 2 production by blood mononuclear cells and inhibits urokinase-induced extracellular proteolysis
62. Physiological consequences of loss of plasminogen activator gene function in mice
63. The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility
64. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease
65. Thrombospondin causes activation of latent Transforming Growth Factor-β in bovine endothelial cells
66. Thrombospondin-1 is a major activator of TGF-β1 in vivo
67. Diversity of function is inherent in matricellular proteins: An appraisal of thrombospondin-1
68. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity
69. Thrombospondins selectively activate one of the two latent forms of transforming growth factor-β present in adrenocortical cell-conditioned medium
70. Activation of rat alveolar macrophage-derived latent transforming growth factor beta-1 by plasmin requires interaction with thrombospondin-1 and its cell surface receptor, CD36
71. Analysis of small latent transforming growth factor-beta complex formation and dissociation by surface plasmon resonance. Absence of direct interaction with thrombospondins
72. Thrombospondin 1 does not activate transforming growth factor beta 1 in a chemically defined system or in smooth-muscle-cell cultures
73. Activation of platelet transforming growth factor-beta 1 in the absence of thrombospondin-1
74. A first or dominant immunization. II. Induced immunoglobulin carries transforming growth factor beta and suppresses cytolytic T cell responses to unrelated alloantigens
75. Intracellular demonstration of active TGF-β1 in B cells and plasma cells of autoimmune mice
76. B lymphocytes secreting IgG linked to latent transforming growth factor-beta prevent primary cytolytic T lymphocyte responses
77. The integrin αvβ6 binds and activates latent TGF-β1: A mechanism for regulating pulmonary inflammation and fibrosis
78. Signaling networks linking integrins and rho family GTPases
79. Radiation-induced transforming growth factor β and subsequent extracellular matrix reorganization in mammary gland
80. Radiation-induced alterations in rat mesangial cell Tgfb1 and Tgfb3 gene expression are not associated with altered secretion of active TGF-β isoforms
81. Vitamin D3 regulation of transforming growth factor-beta system in epithelial and fibroblastic cells - Relationships to plasminogen activation
82. Glucocorticoid-induced activation of latent transforming growth factor-beta by normal human osteoblast-like cells
83. The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis
84. Inhibition of transforming growth factor beta production by nitric oxide-treated chondrocytes: Implications for matrix synthesis
85. The involvement of aryl hydrocarbon receptor in the activation of transforming growth factor-beta and apoptosis
86. IFN-gamma inhibits the production of latent transforming growth factor-beta 1 by mouse inflammatory macrophages
87. Recombinant latent transforming growth factor-β1 has a longer half-life than active transforming growth factor-β1, and a different tissue distribution
88. Pathogenesis of tumor stroma generation: A critical role for leaky blood vessels and fibrin deposition
89. Acidic pH inhibits non-MHC-restricted killer cell functions
90. Transforming growth factor-β2 downregulates HLA-DR antigen expression on human malignant glioma cells
91. Latent forms of transforming growth factor-beta 2 in breast cyst fluid
92. Fibrose superficielle radio-induite et TGF-β1
93. TGF-beta 1 production in radiation nephropathy: Role of angiotensin II
94. Activation of transforming growth factor-beta 1 in diabetic kidney disease
95. Active transforming growth factor-beta in wound repair. Determination using a new assay
96. Deficient activation and different expression of transforming growth factor-beta isoforms in active proliferative diabetic retinopathy and neovascular eye disease
97. Genetic control of the circulating concentration of transforming growth factor type beta 1